Announcement of webinar 【HOW NAFLD ACTIVITY SCORE IS SCORED IN NON-CLINICAL STUDIES】
Today we are excited to invite you to join our Online Linkedin Webinar that will be taking place on May 18th (JST) from 9:30 AM.
In this webinar, we will introduce STAM™ mice and give a lecture on the NAFLD activity score scoring method recommended by the FDA as the primary endpoint of clinical trials.
As you may already know, preclinical models that have a high clinical correlation are extremely important when it comes to successfully developing effective NASH treatments. That is why we highly recommend that you join our free webinar!
Click here to participate ► webinar
At SMC, we have successfully conducted countless drug efficacy studies and are one of the leading experts in the field of NASH.
Please feel free to contact us if you have any questions about SMC, including if you would like more information on this webinar or our experience as a CRO.
■Webinar title：HOW NAFLD ACTIVITY SCORE IS SCORED IN NON-CLINICAL STUDIES
■Webinar Link
■Date： May 18th (Thu) 9:30 – 10:00 AM (JST)
■Agenda
・Introduce about SMC Laboratories
・Introduce about our liver disease mouse model that induces liver cancer from NASH.
・Learn about the NAFLD Activity score
・Achievements with STAM model
The STAM™ model was developed here at SMC Laboratories and is the world's first pathological mouse model to show the progression of NASH to liver cancer.
This model shows a similar pathology to human NASH (steatosis → NASH → liver fibrosis → HCC).